JPRN-jRCT2080220245未知3 期
ong-term safety study of vildagliptin in patients with type 2 diabetes
ovartis Pharma K.K.0 个研究点目标入组 150 人开始时间: 2006年5月22日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Ages Eligible for Study: 20 Years and above, Genders Eligible for Study: Both
- •Inclusion Criteria:
- •- Diagnosis of type 2 diabetes
- •- Patients who have been placed on diet and exercise therapy without achieving target blood glucose levels
- •- Outpatients
排除标准
- •- Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes
- •- Significant cardiovascular complications as defined by the protocol
- •- Significant diabetic complications as defined by the protocol
- •Other protocol-defined inclusion/exclusion criteria may apply
研究者
相似试验
未知
3 期
Open, Long-Term Safety Study With Vildagliptin in Patients With Type 2 Diabetes (as add-on therapy with metformin, thiazolidinedione, alpha-glucosidase inhibitor or rapid-acting insulin secretagogues)Type 2 DiabetesJPRN-jRCT2080221153ovartis Pharma K.K.216
招募中
4 期
An study to assess the safety and efficacy of vildagliptin vs voglibose in management of post-prandial blood sugar in patients with T2DMCTRI/2024/08/072355Dr Mahima V
已完成
不适用
Efficacy and Safety of Vildagliptin in Type 2 DiabetesCTRI/2022/01/039112Cipla Limited1,691
未知
3 期
To assess the efficacy and safety of vildagliptin as add-on therapy to sulfonylurea in patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapyType 2 DiabetesJPRN-jRCT2080220244ovartis Pharma K.K.200
未知
1 期
To Assess the Efficacy and Safety of Vildagliptin in Patients with Type 2 DiabetesType 2 DiabetesJPRN-jRCT2080220150ovartis Pharma K.K.264